PURPOSE: To determine through the analysis of our multi-institutional database whether postoperative adjuvant chemotherapy for upper urinary tract carcinoma with localized invasive upper urinary tract carcinoma (UUTC) is beneficial. METHODS: A study population of 93 patients with pT3N0/xM0 UUTC was eligible for this study. Clinical features evaluated were sex, tumor location, adjuvant chemotherapy status, tumor pathology (histology, grade, infiltrating growth, lymphovascular invasion (LVI)), and cause of death. Cancer-specific survival (CSS) was estimated by Kaplan-Meier method. Prognostic factors related to CSS were analyzed by Cox proportional hazards regression model for multivariate analysis. RESULTS: In pT3 patients, overall 5-year CSS rate was 68.4% and median CSS time was 31 months (range 3-114 months). In the adjuvant chemotherapy group, 5-year CSS rate was 80.8%, whereas 5-year CSS rate was 64.4% in the non-adjuvant chemotherapy group. By multivariate analysis, adjuvant chemotherapy status was significantly associated with CSS (P = 0.008) were sex, tumor grade, tumor histology, and LVI presence. CONCLUSIONS: This study, although it was retrospective study, revealed that adjuvant chemotherapy after RNU may be beneficial in pT3N0/X patients by multivariate analysis. Prospective studies evaluating adjuvant therapy regimens for UTTC are required.
PURPOSE: To determine through the analysis of our multi-institutional database whether postoperative adjuvant chemotherapy for upper urinary tract carcinoma with localized invasive upper urinary tract carcinoma (UUTC) is beneficial. METHODS: A study population of 93 patients with pT3N0/xM0 UUTC was eligible for this study. Clinical features evaluated were sex, tumor location, adjuvant chemotherapy status, tumor pathology (histology, grade, infiltrating growth, lymphovascular invasion (LVI)), and cause of death. Cancer-specific survival (CSS) was estimated by Kaplan-Meier method. Prognostic factors related to CSS were analyzed by Cox proportional hazards regression model for multivariate analysis. RESULTS: In pT3 patients, overall 5-year CSS rate was 68.4% and median CSS time was 31 months (range 3-114 months). In the adjuvant chemotherapy group, 5-year CSS rate was 80.8%, whereas 5-year CSS rate was 64.4% in the non-adjuvant chemotherapy group. By multivariate analysis, adjuvant chemotherapy status was significantly associated with CSS (P = 0.008) were sex, tumor grade, tumor histology, and LVI presence. CONCLUSIONS: This study, although it was retrospective study, revealed that adjuvant chemotherapy after RNU may be beneficial in pT3N0/X patients by multivariate analysis. Prospective studies evaluating adjuvant therapy regimens for UTTC are required.
Authors: Brian R Lane; Armine K Smith; Benjamin T Larson; Michael C Gong; Steven C Campbell; Derek Raghavan; Robert Dreicer; Donna E Hansel; Andrew J Stephenson Journal: Cancer Date: 2010-06-15 Impact factor: 6.860
Authors: Nicholas J Hellenthal; Shahrokh F Shariat; Vitaly Margulis; Pierre I Karakiewicz; Marco Roscigno; Christian Bolenz; Mesut Remzi; Alon Weizer; Richard Zigeuner; Karim Bensalah; Casey K Ng; Jay D Raman; Eiji Kikuchi; Francesco Montorsi; Mototsugu Oya; Christopher G Wood; Mario Fernandez; Christopher P Evans; Theresa M Koppie Journal: J Urol Date: 2009-07-17 Impact factor: 7.450
Authors: Marco Roscigno; Shahrokh F Shariat; Vitaly Margulis; Pierre Karakiewicz; Mesut Remzi; Eiji Kikuchi; Cord Langner; Yair Lotan; Alon Weizer; Karim Bensalah; Jay D Raman; Christian Bolenz; Charles C Guo; Christopher G Wood; Richard Zigeuner; Jeffrey Wheat; Wareef Kabbani; Theresa M Koppie; Casey K Ng; Nazareno Suardi; Roberto Bertini; Mario I Fernández; Shuji Mikami; Masaru Isida; Maurice Stephan Michel; Francesco Montorsi Journal: J Urol Date: 2009-04-16 Impact factor: 7.450
Authors: A Bamias; Ch Deliveliotis; G Fountzilas; D Gika; A Anagnostopoulos; M P Zorzou; E Kastritis; C Constantinides; P Kosmidis; M A Dimopoulos Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: Atiqullah Aziz; Jakub Dobruch; Kees Hendricksen; Luis A Kluth; Andrea Necchi; Aidan Noon; Michael Rink; Florian Roghmann; Roland Seiler; Paolo Gontero; Wassim Kassouf; Shahrokh F Shariat; Evanguelos Xylinas Journal: World J Urol Date: 2017-01-10 Impact factor: 4.226
Authors: Evanguelos Xylinas; Luis Kluth; Malte Rieken; Morgan Rouprêt; Bashir Al Hussein Al Awamlh; Thomas Clozel; Maxine Sun; Pierre I Karakiewicz; Mithat Gonen; Shahrokh F Shariat Journal: Urol Oncol Date: 2016-11-03 Impact factor: 3.498